证券代码：301093 证券简称：华兰股份 江苏华兰药用新材料股份有限公司 投资者关系活动记录表 编号：2023-002 投资者关系活动类别 ☐特定对象调研 ☐分析师会议 ☐媒体采访 业绩说明会 ☐新闻发布会 ☐路演活动 ☐现场参观 ☐其他（请文字说明其他活动内容） 形式 ☐现场 网上 ☐电话会议 参与单位名称及人员姓 线上参与公司2022年度网上业绩说明会的全体投资者 名 时间 2023年05月17日15:00-16:30 地点 价值在线（https://www.ir-online.cn/），采用网络互动方式举 行 | --- | --- | |----------------------|-------------------------------| | | 董事长兼总经理 华一敏先生 | | | 独立董事 柳丹先生 | | 上市公司接待人员姓名 | 保荐代表人 邹晓东先生 | | | 副总经理、财务总监 徐立中先生 | | | 副总经理、董事会秘书 刘雪女士 | | | | | | | | | | 投资者关系活动 1 .（1）华兰股份长期处于破发，给股民一个交代，分红一年给 予分2次来回馈股民（2）贵 ...

证券代码：301093 证券简称：华兰股份 公告编号：2023-040 江苏华兰药用新材料股份有限公司 普遍关注的问题进行回答。欢迎广大投资者积极参与。 特此公告。 江苏华兰药用新材料股份有限公司董事会 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司（以下简称"公司"）已于 2023 年 04 月 24 日在巨潮资讯网上披露了《2022 年年度报告》及《2022 年年度报告摘要》。 为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定 于 2023 年 05 月 17 日（星期三）15:00-16:30 在"价值在线"（www.ir-online.cn） 举办 2022 年度网上业绩说明会，与投资者进行沟通和交流，广泛听取投资者的 意见和建议。 届时出席本次说明会的人员有：公司董事长、总经理华一敏先生，独立董事 柳丹先生，保荐代表人邹晓东先生，副总经理、财务总监徐立中先生，副总经理、 董事会秘书刘雪女士。本次年度业绩说明会将采用网络互动方式举行，投资者通 过访问网址（h ...

Financial Performance - The company's revenue for Q1 2023 was CNY 156,340,882.84, representing a 19.42% increase compared to CNY 130,918,431.95 in the same period last year[4] - Net profit attributable to shareholders was CNY 33,252,865.25, up 6.70% from CNY 31,165,938.51 year-on-year[4] - The net cash flow from operating activities increased by 61.31% to CNY 37,293,788.25, compared to CNY 23,119,604.44 in the previous year[4] - The company reported a significant increase in investment income, which rose by 296.11% to CNY 6,984,776.55 from CNY 1,763,333.33 in the same period last year[10] - The company received government subsidies amounting to CNY 6,753,858.37, an increase of 1101.82% compared to CNY 561,970.31 in the previous year[10] - The company's basic earnings per share increased by 6.49% to CNY 0.246 from CNY 0.231 year-on-year[4] - The company reported a total profit of CNY 38,888,190.97 for Q1 2023, an increase of 6.1% from CNY 36,559,342.51 in Q1 2022[22] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.246, up from CNY 0.231 in the same period last year, representing a growth of 6.5%[23] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,636,844,441.83, a 2.20% increase from CNY 2,580,138,713.97 at the end of the previous year[4] - The company's total current assets at the end of Q1 2023 amounted to ¥2,068,453,656.90, slightly down from ¥2,080,554,351.93 at the beginning of the year[19] - Non-current assets increased to ¥568,390,784.93 from ¥499,584,362.04, representing a growth of 13.8%[19] - Total liabilities as of Q1 2023 were ¥184,999,638.21, compared to ¥164,210,450.60 at the start of the year, indicating an increase of 12.5%[20] - The company's retained earnings rose to ¥408,515,243.41 from ¥375,262,378.16, an increase of 8.9%[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 20,089[12] - Jiangyin Hualan Electromechanical Technology Co., Ltd. holds 20.83% of shares, totaling 28,280,000 shares[12] - Huaxia Life Insurance Co., Ltd. holds 16.17% of shares, totaling 21,956,522 shares[12] - The top ten shareholders include individuals and entities with significant stakes, such as a natural person holding 5.47% (7,426,249 shares)[12] - The total number of restricted shares at the beginning of the period was 38,227,846, with an increase of 1,120,000 shares, bringing the total to 39,347,846[16] - Jiangyin Hualan Electromechanical Technology Co., Ltd. has 28,280,000 restricted shares, which are subject to a lock-up period until May 5, 2025[15] - The company has a significant number of shares under incentive plans, with various individuals holding restricted shares that will unlock in 2023 and 2025[16] - The company has not reported any significant changes in the number of preferred shareholders[14] Operational Insights - Total operating revenue for Q1 2023 reached ¥156,340,882.84, an increase of 19.4% compared to ¥130,918,431.95 in the same period last year[21] - Total operating costs for Q1 2023 were ¥133,470,456.13, up from ¥106,137,828.50, reflecting a year-over-year increase of 25.7%[21] - The cash and cash equivalents at the end of Q1 2023 were ¥134,188,316.72, down from ¥145,509,012.15 at the beginning of the year[19] - Inventory levels increased to ¥129,818,169.16 from ¥119,237,518.81, reflecting an increase of 8.3%[19] - Operating cash flow for Q1 2023 was CNY 37,293,788.25, significantly higher than CNY 23,119,604.44 in Q1 2022, marking an increase of 61.4%[24] - Investment activities resulted in a net cash outflow of CNY 67,068,869.87 in Q1 2023, an improvement from a net outflow of CNY 1,727,470,246.32 in Q1 2022[24] Other Information - The report indicates that there are no other important matters to disclose at this time[17] - The financial statements for the first quarter of 2023 are prepared and available for review[17] - The company experienced a financial expense of CNY 1,104,525.55 in Q1 2023, compared to a financial income of CNY 3,457,426.00 in Q1 2022[22] - Research and development expenses for Q1 2023 were CNY 8,655,646.30, slightly down from CNY 9,236,551.11 in Q1 2022[22] - The company did not report any significant new product launches or market expansions during this quarter[22]

Financial Performance - The company's operating revenue for 2022 was ¥584,137,522.12, a decrease of 28.84% compared to ¥820,866,851.98 in 2021[25]. - The net profit attributable to shareholders for 2022 was ¥93,751,536.87, down 56.60% from ¥216,019,162.93 in 2021[25]. - The net profit after deducting non-recurring gains and losses was ¥64,289,422.91, a decline of 69.95% from ¥213,952,774.28 in the previous year[25]. - The basic earnings per share for 2022 was ¥0.696, a decrease of 65.65% compared to ¥2.026 in 2021[25]. - The total assets at the end of 2022 were ¥2,580,138,713.97, a decrease of 2.01% from ¥2,632,955,496.82 at the end of 2021[25]. - The company reported a net cash flow from operating activities of ¥94,883,342.97, down 56.18% from ¥216,537,730.22 in 2021[25]. - The gross profit margin for the reporting period was 43.63%, a decline of 11.49% compared to the previous year[64]. - The company achieved revenue of 584.14 million yuan, a year-on-year decrease of 28.84%[63]. - The net profit attributable to shareholders was 93.75 million yuan, down 56.60% year-on-year[63]. - The company reported a significant drop in sales volume of pharmaceutical packaging products by 30.60%, primarily due to a sharp decline in orders for vaccine stoppers[70]. Dividend Distribution - The company reported a profit distribution plan to distribute a cash dividend of 3 RMB per 10 shares (including tax) to all shareholders, based on 135,786,667 shares[7]. - The company distributed a cash dividend of 3 yuan per 10 shares, totaling 40,736,000.10 yuan, which represents 100% of the total profit distribution[172]. - The company has no plans for stock dividends or capital reserve transfers, focusing solely on cash dividends for the reporting period[172]. Market and Industry Outlook - The company operates in the pharmaceutical packaging materials industry, which is expected to grow due to factors such as economic growth and an aging population[34]. - The market for pharmaceutical rubber stoppers is large and continues to grow, with a focus on increasing the penetration of film-coated stoppers[34]. - The company is a leading player in the domestic pharmaceutical rubber stopper industry, with significant competition from firms like Huachang Technology and Shandong Pharmaceutical Glass[35]. - The global pharmaceutical rubber stopper market is currently dominated by four companies, with West Pharmaceutical holding over 50% market share, indicating significant growth potential for the company[109]. - The company is committed to developing high-quality pharmaceutical rubber stoppers to capture more market share in the mid-to-high-end market segment[105]. Strategic Initiatives - The company is investing in automation and intelligent factory transformation projects to enhance production capacity for pre-filled medical packaging materials[18]. - The company is expanding its production capacity for medical packaging materials using over-raised funds, indicating a focus on market expansion[18]. - The company plans to enhance automation and smart factory upgrades, as well as expand the production capacity of pre-filled medical packaging materials[35]. - The company aims to achieve dynamic sealing in its new products to mitigate leakage risks during use[81]. - The company is actively seeking consolidation opportunities in the pharmaceutical packaging industry to expand its strategic layout through acquisitions and partnerships[112]. Research and Development - Research and development investment for the year was 36.69 million yuan, a decrease of 12.82% from the previous year[65]. - The company is developing a pre-filled catheter flushing solution to reduce external contamination and improve product competitiveness[81]. - The company is focusing on the domestic market for pre-filled packaging materials, aiming to reduce reliance on foreign products and enhance local production capabilities[82]. - The company is committed to increasing R&D investment to maintain its competitive edge in the pharmaceutical rubber stopper industry[117]. - The company is investing 100 million RMB in R&D for new technologies aimed at enhancing product efficiency[148]. Governance and Compliance - The company has established a robust internal control system to enhance decision-making and operational transparency[113]. - The company held four shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[123]. - The board of directors consists of nine members, including three independent directors, ensuring compliance with governance standards[125]. - The company has established an independent financial accounting system and does not share bank accounts with controlling shareholders[135]. - The company has implemented a series of internal control measures, including management rules and procedures, to ensure compliance and operational integrity[177]. Social Responsibility and Sustainability - The company has committed a total of ¥2,659,146.94 to social welfare and charity initiatives during the reporting period, supporting various educational and community projects[187]. - The company emphasizes environmental protection and sustainable development, promoting advanced and energy-efficient technologies[186]. - The company actively engages in social responsibility, ensuring legal compliance and maintaining good relationships with stakeholders[183]. - The company is committed to sustainability and is integrating eco-friendly practices into its production processes, aligning with global trends[143]. Future Projections - Future plans and forward-looking statements in the report do not constitute a substantive commitment to investors, highlighting the need for risk awareness[6]. - The company plans to enhance its digital factory capabilities with a top-level design contract worth 18.99 million yuan with Huawei[57]. - The company has set ambitious performance guidance for the upcoming fiscal year, projecting a revenue growth rate of over 15%[143]. - The company plans to launch three new products in 2023, focusing on innovative drug delivery systems[193]. - Future outlook includes a projected revenue growth of 10-15% for 2023, driven by increased market demand and new product launches[195].

证券代码：301093 证券简称：华兰股份 江苏华兰药用新材料股份有限公司 投资者关系活动记录表 编号：2022-001 | --- | --- | --- | --- | --- | --- | --- | |----------------------------------|-------------------------------------------------------------|------------------------------------------------------------------|-------|--------------------------|-------|-------| | | | | | | | | | 投资者关系活动类别 ☐特定对象调研 | | ☐分析师会议 | | | | | | | ☐ 媒体采访 | 业绩说明会 | | | | | | | ☐ 新闻发布会 | ☐路演活动 | | | | | | | ☐ 现场参观 | | | | | | | | ☐ 其他（请文字说明其他活动内容） | | | | | | | 形式 ☐ | 现场 网上 | ...

证券代码：301093 证券简称：华兰股份 江苏华兰药用新材料股份有限公司 投资者关系活动记录表 编号：2022-002 | --- | --- | --- | --- | --- | --- | |----------------------------------|----------------------------------|------------------------------------------------------|-------|------------------------------------------------------|-------| | | | | | | | | 投资者关系活动类别 ☐特定对象调研 | | ☐分析师会议 | | | | | | ☐ 媒体采访 | ☐ 业绩说明会 | | | | | | ☐ 新闻发布会 | ☐路演活动 | | | | | | 现场参观 | | | | | | | ☐ 其他（请文字说明其他活动内容） | | | | | | 形式 | 现场 ☐ 网上 | ☐ 电话会议 | | | | | 参与单位名称及人员姓名 | | | | ...

证券代码：301093 证券简称：华兰股份 江苏华兰药用新材料股份有限公司 投资者关系活动记录表 编号：2022-003 | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------|-----------------|------------------------------------------------------|-------------|-------|-------|-------| | | | | | | | | | 投资者关系活动类别 ☐特定对象调研 | | | ☐分析师会议 | | | | | | ☐ 媒体采访 | ☐ | 业绩说明会 | | | | | | ☐ 新闻发布会 | ☐路演活动 | | | | | | | 现场参观 | | | | | | | | ☐ | 其他（请文字说明其他活动内容） | | | | | | 形式 | 现场 ☐ | 网上 ☐ 电话会议 | | | | | | 参与单位名称及人员姓名 | 泰康资产 | 傅洪哲、信达证券 武浩 | | | | ...

Financial Performance - The company's revenue for Q3 2022 was ¥139,016,329.90, a decrease of 43.13% compared to the same period last year[4] - Net profit attributable to shareholders was ¥20,505,728.26, down 73.28% year-on-year[4] - The basic earnings per share decreased by 79.95% to ¥0.1523[4] - Total operating revenue for the third quarter was CNY 407,250,718.10, a decrease of 36.6% compared to CNY 642,406,273.67 in the same period last year[23] - The net profit for the third quarter was 76,654,882.51 CNY, down 58.5% from 184,607,274.91 CNY year-over-year[24] - Basic and diluted earnings per share were both 0.569 CNY, compared to 1.828 CNY in the previous year[25] - The company reported a total operating income of 533,151,748.79 CNY, down from 616,211,339.50 CNY year-over-year[25] Cash Flow - The company reported a significant reduction in cash flow from operating activities, with a net cash flow of ¥68,235,480.89, down 36.24% year-to-date[4] - The net cash flow from operating activities decreased by 36.24% to ¥68,235,480.89 compared to the same period last year due to a reduction in sales revenue[12] - Cash flow from operating activities generated a net amount of 68,235,480.89 CNY, a decline of 36.3% from 107,020,587.92 CNY in the same period last year[25] - The net cash flow from investing activities saw a significant increase of 2049.54%, amounting to -¥1,692,203,069.54, attributed to cash management investments and participation in equity funds[12] - Cash flow from investing activities resulted in a net outflow of 1,692,203,069.54 CNY, compared to an outflow of 78,723,826.41 CNY in the previous year[26] - The net cash flow from financing activities decreased by 508.50% to -¥132,530,515.94, primarily due to profit distribution during the period[12] - The net increase in cash and cash equivalents dropped dramatically by 31822.95% to -¥1,756,872,945.47, reflecting a substantial decrease in net cash flow from investing and financing activities[12] - Cash and cash equivalents decreased by 1,756,872,945.47 CNY during the quarter, contrasting with an increase of 5,538,176.03 CNY in the same period last year[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,526,098,594.25, a decrease of 4.06% from the end of the previous year[4] - The total assets as of September 30, 2022, were CNY 2,526,098,594.25, a slight decrease from CNY 2,632,955,496.82 at the beginning of the year[22] - Current assets totaled CNY 2,085,494,598.27, down 8.9% from CNY 2,289,422,795.88 at the start of the year[21] - Non-current assets increased to CNY 440,603,995.98, up 28.3% from CNY 343,532,700.94 at the beginning of the year[21] - Total liabilities decreased to CNY 127,266,985.24 from CNY 216,512,103.42, a reduction of 41.3%[22] - The company's equity attributable to shareholders was CNY 2,398,831,609.01, slightly down from CNY 2,416,443,393.40 at the beginning of the year[22] Investments and Expenses - The company experienced a 36.61% decline in total revenue year-to-date, primarily due to a substantial decrease in orders for vaccine rubber stoppers[11] - The company reported a 100% increase in investment income to ¥10,767,767.06 from cash management products[11] - The company’s other non-current financial assets increased by 100% to ¥25,500,000.00 due to investments in equity funds[9] - The company’s construction in progress increased by 151.00% to ¥85,465,239.55, reflecting ongoing projects[10] - The company’s financial expenses decreased significantly by 218.99% due to reduced bank loan interest expenses[11] - Research and development expenses were CNY 25,986,410.95, a decrease of 10.4% compared to CNY 29,153,591.30 in the previous year[23] - Cash paid for various taxes decreased by 53.24% to ¥41,832,235.26, reflecting reduced tax payments[13] - Cash received from investment recoveries was ¥810,000,000.00, marking a 100% increase due to cash management actions[13] - Cash paid for investment activities reached ¥2,422,500,000.00, representing a 100% increase as the company engaged in cash management and equity fund investments[13] - The company distributed dividends amounting to ¥92,147,725.94, a significant increase of 2254.60% compared to the previous year[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,592, with the top ten shareholders holding significant stakes, including Jiangyin Hualan Electromechanical Technology Co., Ltd. at 21.00%[14] Audit and Reporting - The company has not undergone an audit for the third quarter report[27] - The company’s total assets and liabilities were not disclosed in the provided documents, indicating a need for further financial details in future reports[24]